EGFR and non-small cell lung carcinoma: Of them, the clinical characteristics of the 84 patients with EGFR-mutant NSCLC who had enough samples obtained from either before EGFR-TKIs treatment or after development of acquired resistance to EGFR-TKIs were shown in Table 1 and that of the other 5 patients who had matched samples were shown in Table 2.